KELVIN P. DAVIES, M.Sc., Ph. D.
POSITION TITLE
Professor of Urology,
Professor of Physiology and Biophysics.
CONTACT INFORMATION
Albert Einstein College of Medicine,
Department of Urology,
Room F. 742,
Bronx, NY 10461.
Tel.: 718 430 2914
Email:
I. EDUCATION
INSTITUTION AND LOCATION / DEGREE / MM/YY / FIELD OF STUDY
University of Sheffield, UK / BSc / 06/85 / Biochemistry
University of Birmingham, UK / MSc / 06/86 / Toxicology
University of Zurich, Switzerland / PhD / 06/91 / Biochemistry
II. PERSONAL STATEMENT
I am presently a Professor in the Departments of Urology and Physiology & Biophysics andDirector of the Urology Basic Research Laboratoriesat Albert EinsteinCollege of Medicine and. I have a background in Biochemistry and Molecular Biology. Since 2001, when I joined the Department of Urology at Einstein, I have applied these techniques to understanding the biochemical and molecular mechanisms that underlie benign and oncologic urogenital disease. The goal of these studies is to developing clinically translational strategies their treatment of urogenital disease. My publications span both basic science and Urology and I have authored papers in top ranked, peer reviewed journals, such as Science, Nature Genetics, FASEB, Journal of Biological Chemistry, Molecular and Cellular Proteomics as well as the top raked Urological research journals. My work has been funded by several grants;I have been Principal Investigator on 7 NIH grants and am currently Principal Investigator on an NIH R01 and two NY State Department of Health grants.
III. POSTGRADUATE TRAINING
1991-1993 Post-doctoral Associate, Dept. of Biochemistry, University of Berne, Switzerland.
1993-1996 Post-doctoral Research Associate, Dept. of Molecular Parasitology, Rockefeller University, New York, USA.
1997-2001 Post-doctoral Research Associate: Dept. Molecular Genetics, Albert Einstein College of Medicine, New York, USA.
2001-2008 Assistant Professor of Urology, Albert Einstein College of Medicine, New York, USA.
2008-2013 Associate Professor of Urology, Albert Einstein College of Medicine, New York, USA.
2010-2013 Associate Professor of Physiology and Biophysics, Albert Einstein College of Medicine, New York, USA.
2011-Director of Urology Basic Research Laboratories, Albert Einstein College of Medicine, New York, USA.
2013- Professor of Urology, Albert Einstein College of Medicine, New York, USA.
2013-Professor of Physiology and Biophysics, Albert Einstein College of Medicine, New York, USA.
IV. PROFESSIONAL SOCIETY MEMBERSHIP
2005- Member of the American Urological Association.
2005- Member of the Sexual Medicine Society of North America.
2005- Member of the International Society for Sexual Medicine.
IV. AWARDS AND HONORS
2002 E. Darracott Vaughan Young Investigator Award, Kidney and Urology Foundation of America.
2002 Young Investigator Award, International Society for Sexual and Impotence Research.
V. OTHER PROFESSIONAL ACTIVITIES
Teaching and Mentoring at Albert Einstein College of Medicine.
Post-doctoral students mentored: Dr. Li Wang and Dr. Amarnath Murkherjee.
Junior Faculty mentored:Dr. Yi Wang (basic science), Dr. Joshua Stern and Nitya Abraham (Clinical faculty).
Reproductive Endocrinology and Infertility Fellowship: (Dr. Rani Fritz).
Positions in Albert Einstein College of Medicine
Chair, Committee on Committee’s.
Senate Representative for Department of Urology.
Member of the CAP (Promotions Committee) for promotion to Associate Professor.
Member of the Faculty Interaction Committee.
Member of the Benefits Committee.
National Review Committees
2009- NIH peer review committee for challenge grants.
2009- Peer review of grants for the Italian Ministry of Health.
2010- Peer review of grants for Natural Sciences and Engineering, Research Council of Canada.
2013- Peer review of Grants for Diabetes UK, UK.
2013- Peer review of grants for the National Science Center of Poland.
2013- NIH peer review/ study section for conflict of interest (NIDDK).
Reviewer/Editorial Board
Editorial Board of Journal of Sexual Medicine; Frontiers in Integrative and Regenerative Pharmacology.
Reviewer for Journal of Sexual Medicine, Journal of Urology, PLoS One, Current Urology, Neurourology and Urodynamics, Cell Biochemistry & Function, Asian Journal of Andrology.
Scientific Advisory Boards
NanoBioMed:
MicroCures:
VI. RESEARCH
Ongoing Research Support:
Grant: 1R01DK107807-01 (PI: Davies, K.P.)
Title: Opiorphin as a master regulator of pathways leading to priapism.
Project Period:01/15/2016-11/30/19
Role on Project: Principal Investigator (35% effort)
Funding Source: NIH/NIDDK
Total Costs: $1,971,236Direct Costs:$1,180,100Indirect Costs:$791,136
Grant: DOH01-CARTID-2015-00041 (MPI: Davies, K.P. Suadicani, S.O., Sharp, D.S.)
Title:Harnessing Microtubules to Enhance Urogenital Functionafter Spinal Cord Injury.
Project Period11/01/2015-10/31/2020
Role on Project:Co-Principal Investigator (20% effort)
Funding Source:New York State Health Department, The New York State Spinal Cord Injury Research Board, Spinal Cord Injury ResearchProgram.
Total Costs:$1,198,141Direct Costs: $1,078,327Indirect Costs:$119,814
Grant: DOH01-CARTID-2015-00041 (Supplement) (MPI: Davies, K.P. Suadicani, S.O., Sharp, D.S.)
Tile:Harnessing Microtubules to Enhance Urogenital Function after Spinal Cord Injury.
Project Period: 02/01/16-08/31/2016
Role on Project:Co-Principal Investigator (5% effort)
Funding Source:New York State Health Department, The New York State Spinal Cord Injury Research Board, Spinal Cord Injury ResearchProgram.
Total Costs: $329,997 Direct Costs: $299,988 Indirect Costs:$29,989
Grant: Prostate Cancer Research, RFA # 1410200115(PI: Davies, K.P.)
Title:Potential role of Opiorphin in supporting tumor growth through angiogenesis.
Project Period:11/01/2015-10/31/2017
Role on Project: Principal Investigator (30% effort)
Funding Source:New York State Health Department
Total Costs $330,000Direct Costs: $300,000Indirect Costs:$30,000
Grant: Lilly Post-doctoral fellowship (PI: Wang, Yi)
Project Period:09/1/2013-08/31/2018
Role: Mentor
Funding Source: Eli Lilly, Inc.
Title: Role of the MaxiK potassium channels in the bladder urothelium.
Total Costs:Post-Doctoral salary and $45,000 laboratory supplies and expenses.
Grant:American Societyof Nephrology Career Development Grant (PI: Stern, Josh).
Project Period: 07/01/2016-06/30/2018
Role: Mentor
Title:Evidence for a Distinct Gut Microbiome in Kidney Stone Formers.
Total Costs: $200,000 Direct Costs: $180,000Indirect Costs: $20,000
Pending Research Support
Grant: R01DK109314-01A1 (MPI: Davies, K.P. (Contact), Sharp, D.S.)
Title:The microtubule cytoskeleton as a novel target for cavernous nerve regeneration after prostatectomy.
Project Period:12/01/2016-11/30/2021
Role on Project:Co-Principal Investigator (20% effort)
Funding Source: NIH/NIDDK
Total Costs: $3,239,994.00Direct Costs:$2,170,796Indirect Costs:$1,069198
Grant: P20DK112078-01 (PI/Center Director: Davies, K.P.)
Title:Development of a nanotechnology resource center to advance urological research.
Project Period:12/01/2016-11/30/2018
Role on Project: Principal Investigator (20% effort)
Funding Source: NIH/NIDDK
Total Costs: $668,000Direct Costs:$400,000Indirect Costs:$268,000
Grant: R21DK108097-01A1 (MPI/Davies, K.P., Stern, J. (Contact).)
Title:Evidence for a Distinct Gut Microbiome in Kidney Stone Formers
Project Period:07/01/2016-06/30/2018
Role on Project:Co-Principal Investigator (10% effort)
Funding Source: NIH/NIDDK
Total Costs: $459,250Direct Costs:$275,000Indirect Costs:$184,250
Grant: R41DK112476-01 (MPI: Davies, K.P., Sharp, D.S.(Contact).)
Title:A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical Prostatectomy
Project Period:12/01/2016-11/30/2017
Role on Project:Co-Principal Investigator (10% effort)
Funding Source: NIH/NIDDK
Total Costs: $224,804Direct Costs:$146,000Indirect Costs:$78,804
Completed Research Support:
Grant: 2R56DK087872-04 (PI: Davies, K.P.)
Title: Opiorphin as a master regulator of pathways leading to priapism.
Project Period 09/15/2014-07/31/2015
Role on Project: Principal Investigator
Funding Source: NIH/NIDDK
Grant: R01DK087872-01A1(PI: Davies, Kelvin P)
Title: Involvement of opiorphins and polyamine synthesis in the development of priapism
Project Period 09/15/2011-07/31/2014 (no cost extension till 07/31/2015)
Role on Project: Principal Investigator
Funding Source: NIH/NIDDK
Grant: SBIR (Ion Channel Innovations, Inc., PI: Tar, M.T.)
Title: Gene transfer to treat urinary urgency, frequency, nocturia & incontinence.
Project Period: 09/01/2011-08/31/2013
Role on Project: Consortium Principal Investigator
Funding Source: NIH/NIDDK
Grant: SBIR (Ion Channel Innovations, Inc.,PI: Jacobs, S.)
Title: Development of hMaxiK bladder wall injection for overactive bladder treatment.
Project Period: 09/15/2012-08/31/2014
Role on Project: Consortium Principal Investigator
Funding Source: NIH/NIA
Grant: R01 (PI: Davies, Kelvin, P)
Title: The Role of Vcsa1 in Erectile Function
Project Period: 7/1/2007 – 6/30/2011
Role: Principal Investigator
Funding Source: NIH/NIDDK
Grant: R01 (PI: Disanto, Michael)
Title: Role of calcium sensitization in diabetes-induced erectile dysfunction
Project Period: 7/1/2007 – 6/30/2011
Role:Co- Investigator
Funding Source: NIH/NIDDK
Grant: R21 (PI: Davies, Kelvin, P)
Title: Vcsa1 (hSMR3A) as a Marker for Diabetes
Project Period: 7/1/2007 – 6/31/2009
Role: Principal Investigator
Funding Source: NIH/NIDDK
Grant: K01 (PI: Davies, Kelvin, P)
Title: Regulation of Slo Splicing in the Urogenital System
Project Period: 4/1/2004 – 3/31/2007
Role: Principal Investigator
Funding Source: NIH/NIDDK
Grant:R21 (PI: Chance, Mark, R)
Title: Proteomic Approaches to Type I diabetes Progression
Project Period: 10/01/2004-9/30/2006
Role: Co-Investigator
Funding Source: NIH/NIDDK
Young Investigator Award, Kidney and Urology Foundation of America
Project Period:7/01/2002- 6/30/2003
Role: Principle Investigator
VII. BIBLIOGRAPHY
I have authored more than 50 scientific publications. The list is available on myNCBI:
Original communications in reviewed journals
1)Davies, K. P., Zahner, H. and Kohler, P. (1989) Litomosoides carinii: Mode of action in vitro of benzothiazole and amosconate derivatives with antifilarial activity. Exp. Parasitol. 68, 382-391.
2)Davies, K. P. and Kohler, P. (1990) The role of amino acids in the energy generating pathways of Litomosoides carinii. Mol. Biochem. Parasitol. 41, 115-124.
3) Kohler, P., Davies, K. P. and Zahner, H. (1992) Review: Activity, mechanism of action and pharmacokinetics of 2-tert-butyl-benzothiazole and CGP 6140 (amocarzine) antifilarial drugs. Acta Tropica 51, 195-211.
4) Wasser, M., Hess-Bienz, D., Davies, K. P. and Solioz, M. (1992) Cloning and disruption of a putative NaH-antiporter gene of Enterococcus hirae. J. Biol. Chem. 267, 5396-5400.
5) Davies, K. P. and Solioz, M. (1992) Assessment of uncoupling by amiloride analogs. Biochemistry 31, 8055-8058.
6) Solioz, M. and Davies, K. P.(1994) Operon of Vacuolar-type Na+ATPase of Enterococcus hirae. J. Biol. Chem. 269, 9453-9469.
7) Muñoz-Jordán JL, Davies K.P. and Cross GA. (1996) Stable expression of mosaic coats of variant surface glycoproteins in Trypanosoma brucei. Science 272(5269):1795-7.
8)Davies, K. P., Carruthers, V. B. and Cross, G.A.M. (1997) Locus Stabilisation Elements in the co-transposed region of the Trypanosoma brucei variant surface glycoprotein expression site. Mol. Biochem. Parasitol. 86, 163-177.
9)Davies, K. P. and Kalpana, G.V. (1998) Integration of Retroviruses into a Predetermined Site NATO ASI series. H 105, 71-75.
10) Cheng SW, Davies KP, Yung E, Beltran RJ, Yu J, Kalpana GV. (1999) c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet. 22(1):102-5.
11) Craig, E., Zhang, Z.K., Davies K.P and Kalpana, G.V. (2002) A masked NES in INI1/hSNF5 mediates hCRM1-dependent nuclear export: implications for tumorigenesis. EMBO J. 21, 31-42.
12) Zhang, Z.K., Davies, K.P. Allen, J., Zhu, L., Pestell, R.G., Zagzag, D. and Kalpana, G.V. (2002) Cell Cycle Arrest and Repression of CyclinD1 transcription by INI1/hSNF5. Mol. Cell. Biol. 22, 5975-88.
13) Lagaud, G., Davies K.P., Venkateswarlu, K. and Christ G.J. (2002) The physiology, pathophysiology and therapeutic potential of gap junctions in smooth muscle. Curr Drug Targets, 3 (6), 427-40.
14) Melman, A., Zhao, W., Davies, K.P., Bakal, R. and Christ, G.J. (2003) The Successful Long-Term Treatment of Age-Induced Erectile Dysfunction with the HSLO/Maxi-K Gene J. Urol. 170, 285-90.
15) Christ, G.J. , Day, N., Santizo, C., Sato, Y., Zhao, Sciafani, T., Bakal, R W. Salaman, M., Davies, K.P. and Melman, A. (2004) Intracorporal injection of hSlo CDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol., 287, H1544-53.
16) Melman, A., Bar-Chama, N., McCullough, A., Davies, K.P., and Christ, G. (2005) The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur Urol. 48, 314-8
17) Brink, P.R., Valiunas, V., Wang, H.Z., Zhao, W., Davies, K.P. and Christ, G.J. (2006) Experimental diabetes alters connexin43 derived gap junction permeability in short-term cultures of rat corporeal vascular smooth muscle cells. J Urol., 175, 381-6.
18) Tong, Y., Tar, M., Davelman, F., Christ, G., Melman, A. and Davies, K.P. (2006) Vcsa1 (SMR-1) as a Marker for Erectile Dysfunction. BJU Int., 98(2):396-401.
19) Melman, A, Bar-Chama, N., McCullough, A., Davies, K.P., and Christ, G.J. (2006) hMaxi-K gene transfer in males with erectile dysfunction: Results of the first human trial. Human Gene Therapy. 17, 1165-1176.
20)Davies, K.P., Zhao, W., Tar, M., Figueroa, J.C., Desai, P., Verselis, V., Kronengold, J., Wang, H.Z., Melman, A. and Christ, G.J. (2007) Diabetes-Induced Changes in the Alternative Splicing of the Slo Gene in Corporal Tissue. Eur Urol., 52, 1229-1237.
21)Davies, K.P. Stanevsky, Y. Moses, T., Chang, J,S., Chance, M. and Melman, A. (2007) Ageing causes cytoplasmic retention of MaxiK channels in Rat Corporal Smooth Muscle Cells. IJIR 19, 371-377.
22)Davies, K.P*, Hipp, J.D., Tar, M, Valcic, M, Knoll, A.M., Melman, A. and Christ, G.J. (2007) Using GeneChips to Identify Organ-Specific, Smooth Muscle Responses to Experimental Diabetes: Potential Applications to Urologic Diseases. BJU Int. 99, 418-30 *=co-first author
23)Davies K.P., Tar M, Rougeot C, Melman A. (2007) Sialorphin (the mature peptide product of Vcsa1) relaxes corporal smooth muscle tissue and increases erectile function in the ageing rat. BJU Int. 99, 431-5.
24) Melman, A., Bar-Chama, N., McCullough, A., Davies, K.P. and Christ, G. (2007) Plasmid-based gene transfer for treatment of erectile dysfunction and overactive bladder: results of a phase I trial. Isr Med Assoc J., 9,143-6
25) Tong, Y., Monrose, V., DiSanto, M., Melman, A. and Davies, K.P. (2007) hSMR3A as a marker for patients with erectile dysfunction. J Urol. 178, 338-343.
26) Melman, A., Biggs, G., Davies, K.P., Zhao, W.Z., Tar, M.T. and Christ, G.J. (2008) Gene transfer with a vector expressing Maxi-K from a smooth muscle-specific promoter restores erectile function in the aging. Gene Therapy, 15 364-370.
27) Tong, Y., Tiplitsky, S.I., Tar, M.T., Melman, A. and Davies, K.P. (2008) Transcription of G-protein coupled receptors in corporal smooth muscle is regulated by sialorphin (an endogenous neutral endopeptidase inhibitor). J. Urology. 180, 760-766.
28) Yohannes, E., Chang, J., Christ, G.J., Davies, K.P. and Chance, M.R. (2008) Proteomics analysis identifies molecular targets related to diabetes mellitus associated bladder dysfunction. Mol Cell Proteomics, 7, 1270-1285.
29) Tong, Y., Tar, M.T., Melman, A. and Davies, K.P.(2008) The Opiorphin gene (ProL1) and its homologues function in erectile physiology. BJU lnt., 102, 736-740.
30) Chua, R.G., Calenda, G., Zhang, X., Siragusa, J., Tong, Y, Tar, M., Aydin, M., DiSanto, M.E., Melman, A. and Davies, K.P.(2009) Testosterone Regulates Erectile Function and Vcsa1 Expression in the Corpora of Rats. Mol Cell Endocrinol. 303(1-2):67-73.
31) Calenda, G., Tong, Y, Tar, M., Lowe, D., Siragusa, J., Melman, A. and Davies, K.P.(2009) Vcsa1 acts as a marker of the recovery of erectile function following both gene therapeutic and pharmacological interventions improving erectile function. J Urol. 181(6):2806-15.
32) Sorin, M., Cano, J., Das, S., Mathew, S., Wu, X., Davies, K.P., Shi, X., Cheng, S.W., Ott, D, Kalpana G.V. (2009) Recruitment of a SAP18-HDAC1 complex into HIV-1 virions and its requirement for viral replication. PLoS Pathog. 5(6):e1000463.
33) Melman, A., Zotova, E, Kim, M., Arezzo, J, Davies, K.P., DiSanto, M. and Tar, M. (2009) Longitudinal studies of time dependent changes in both bladder and erectile function after STZ-induced diabetes in the same F344 male rats. BJU Int. 104(9):1292-300.
34) Kanika, N., Tar, M., Tong, Y., Kuppam, D., Melman, A and Davies, K.P.(2009) The mechanism of opiorphin-induced experimental priapism in rats involves activation of the polyamine synthetic pathway. Am J Physiol Cell Physiol. 297(4):C916-27.
35) Christ, G.J., Andersson. K.E., Williams, K., Zhao, W., D’Agostino, R., Kaplan, J., Aboushwareb, T., Yoo, J., Davies, K.P., Calenda, G., Sellers, R. and Melman, A. (2009) Smooth muscle-specific gene transfer with the human Maxi-K channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgous monkeys. Eur. Urol. 56(6), 1055-1066.
36) Yohannes, E., Chang, J., Tar, M.T., Davies, K.P., and Chance, M.R. (2010) Molecular Targets for Diabetes Mellitus Associated Erectile Dysfunction. Molecular and Cellular Proteomics. 9 (3), 565-78.
37) Kanika, N.D., Melman, A. and Davies, K.P. (2010). Experimental priapism is associated with increased oxidative stress and activation of protein degradation pathways in corporal tissue. Int J Impot Res;22(6):363-73.
38) Han, G, Tar, M, Kuppam, D.S., Friedman, A, Melman, A., Friedman, J. and Davies, K.P. (2010) Nanoparticles as a novel delivery vehicle for therapeutics targeting erectile dysfunction. J Sex Med. 2010 Jan;7(1 Pt 1):224-33.
39) Kanika, N., Chang, J., Tong, Y., Tiplitsky, S., Lin, J., Yohannes, J., Tar, M., Chance, M., Christ, G., Melman, A. and Davies, K.P. (2010). Oxidative Stress Status Accompanying Diabetic Bladder Cystopathy Results in the Activation of Protein Degradation Pathways. BJU Int. 107(10):1676-84.
40) Calenda, G., Suadicani, S., Iglesias, R., Spray, D., Melman, A., and Davies, K.P. (2011) Silencing MaxiK activity in corporal smooth muscle cells initiates compensatory mechanisms to maintain calcium homeostasis. J. Sex Med. Aug;8(8):2191-204.
41) Calenda, G., Tong, Y., Kanika, N.D., Tar, M.T., Suadicani, S.O., Xhang, X., Melman, A,, Rougeot, C., Davies, K.P.(2011) Reversal of Diabetic Vasculopathy in a Rat Model of Type 1 Diabetes by Opiorphin-Related Peptides. Am J Physiol Heart Circ Physiol. 301(4):H1353-9.
42) Calenda, G., Strong, T.D., Pavlovich, C.P., Schaeffe,r E.M., Burnett, A.L., Yu, W., Davies, K.P., Bivalacqua, T.J. (2012) Whole genome microarray of the major pelvic ganglion after cavernous nerve injury: new insights into molecular profile changes after nerve injury. BJU Int. 109 (10) 1552-64.
43) Fu, S. Tar, M.T., Melman, A. and Davies, K.P. (2014) Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells. FASEB Journal, 28(8):3633-44
44) Wang, Y., Tar, M.T., Wang, H.Z., Fu, S., Melman, A. and Davies, K.P. (2014) Diabetes induced changes in tension and phasic contractions of isolated bladder strips correlate with modulated Kv7 channel activity. International Journal of Urology, 21(10):1059-64.
45) Tar, M.T., Martinez, L.R., Nosanchuk, J.D. and Davies, K.P. (2014) An animal model for the effects of methamphetamine on erectile function. Andrology 2(4):531-6
46) Bosler, J., Davies K.P. and Neal-Perry, G. (2014) Peptides in Seminal Fluid and their Role in Infertility: A potential role for opiorphin inhibition of neutral endopeptidase activity as a factor in sperm motility. Reproductive Sciences. 21(11):1334-40.
47) Tar, M.T., Cabrales, P., Mahantesh, N., Nacharaju, P., Friedman, A., Friedman, J. and Davies, K.P. (2014)Nanoparticles encapsulating NO can increase intracorporal pressure and elicit spontaneous erections in a rat model of radical prostatectomy.J Sex Med 11(12) 2903-14. PMID: 25302850
48)Fu, S., Davies, K.P.(2015) Opiorphin-dependent upregulation of CD73 (a key enzyme in the adenosine signaling pathway) in corporal smooth muscle cells exposed to hypoxic conditions and in corporal tissue in pre-priapic sickle cell mice. Int J Impot Res. 27(4); 140-5. PMID: 25833166
49)Ahmadi, M, Lee, H.H., Sanchez D.A., Friedman A.J., Tar M.T., Davies K.P., Nosanchuk J.D., Martinez, L.R. (2016)Sustained nitric oxide releasing nanoparticles induce cell death in Candida albicans yeast and hyphal cells preventing biofilm formation in vitro and in a rodent central venous catheter model. Antimicrob Agents Chemother. 60(4); 2185-94. PMID: 26810653
50) Stern, J.M., Moazami, S., Qiu,Y., Kurland, I. Chen, Z., Agalliu, I., Burk, R., Davies, K.P.(2016) Evidence for a Distinct Gut Microbiome in Kidney Stone Formers Compared to Non-stone Formers (In Press).
Chapters in books and review articles
1)Davies, K. P.(1991) Biochemical mode of action of compounds recently developed against filarial parasites. Ph. D. Thesis.
2) Melman, A. and Davies, K.P. Gene therapy of the urogenital system (Chapter 91) (2008) Textbook of reconstructive urologic surgery. Ed. Montague, D., Gill, I., Angermeier, K. and Ross, J. Published by Informa Healthcare
3)Davies, K.P. and Melman, A. (2008) Markers of Erectile Dysfunction. Indian J. Urol. 24, 269-274.
4)Davies, K.P. (2009) The Role of Opiorphins (Endogenous Neutral Endopeptidase Inhibitors) in Urogenital Smooth Muscle Biology. J Sex Med.;6 Suppl 3:286-91.
5) Melman, A and Davies, K.P. (2009) Gene Therapy in the Management of ED; Past, Present and Future. In Press: The Scientific World Journal. 9, 846-54.
6) Melman A, Davies K.P. (2010) Gene therapy for erectile dysfunction: what is the future? Curr Urol Rep;11(6):421-6.
7) Davies, K.P. (2012) Erectile Dysfunction. In “Muscle: Fundamental Biology and Mechanisms of Disease”. Eds Hill, J.A. and Olsen, E.N. (Elsevier). Chapter 102, 1339-1346.
8) Davies, K.P. (2015)Development and therapeutic applications of nitric oxide releasing materials to treat erectile dysfunction. Future Science OA.1(1): FSO53.PMID: 27019746.
9) Musicki, B., Bella, A.J., Bivalacqua, T.J., Davies, K.P., DiSanto, M.E., Gonzalez-Cadavid, N.F., Hannan, J.L., Kim, N.N., Podlasek, C.A., Wingard, C.J. and Burnett, A.L. (2015) Basic Science Evidence for the Link Between Erectile Dysfunction and Cardiometabolic Dysfunction. J Sex Med. 12(12):2233-55. PMID: 26646025.
Invited Talks (since 2007-)
1) Sexual Medicine Society of North America Annual Meeting. Toronto, Oct 16, 2008. “Update on Gene Therapy for Erectile Dysfunction”.
2) 1199SEIU League Training and Upgrading Fund/ Institute for Continuing Education. New York, June 4, 2011. "The Next Generation of Treatments for Erectile Dysfunction".